Spots Global Cancer Trial Database for Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma

Official Title: A Phase II Study of Hu1D10 in Recurrent Hodgkin's Disease

Study ID: NCT00055783

Conditions

Lymphoma

Interventions

apolizumab

Study Description

Brief Summary: RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have progressive or recurrent Hodgkin's lymphoma.

Detailed Description: OBJECTIVES: * Determine the response rate of patients with recurrent Hodgkin's lymphoma treated with monoclonal antibody Hu1D10. * Determine the duration of response and progression-free survival of patients treated with this drug. * Determine the toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive monoclonal antibody Hu1D10 IV over 2 hours. Treatment repeats weekly for a total of 4 doses in the absence of disease progression or unacceptable toxicity. Patients are followed at weeks 5 and 8 and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 9-24 patients will be accrued for this study within approximately 12 months.